Table 1.

Effects of siRNA/Inhibitor treatments on sensory epithelia proliferation

siRNA/Inhibitor Treatment	Inhibit Proliferation	Average Fold Knockdown	Regeneration Pathway/Category
CEBPG	Yes	−3.92	AP-1 Pathway
JNK inhibitor	Yes
JUND	Yes	*
BTAF1	Yes	−1.57	AP-1 siRNA Commonalities
LRP5	Yes	−5.71
RARA	Yes	−1.41
PAX2	Yes	−1.61	Pax Pathway
PAX3	No	−1.61
PAX5	Yes	*
PAX7	No	−1.72
MYT1L	No	*	AP-1/Pax siRNA Commonalities
WNT4	Yes	−2.27
CUTL1	Yes	−1.86	Cell Cycle
p27KIP	No	−2.93
ID1	No	−1.48
CBX3	No	−4.15	Polycomb Complex
CBX4	No	−1.09
EZH2	No	−1.87
IGF inhibitor	No		Pathway Inhibitors
MAPK inhibitor	Yes
SHH inhibitor	No
HRY	No	−1.30	Notch Signaling
BCL11A	No	−1.35	Common to all tissues/damage
TRIP15	No	−1.12
CTNNB1	No	−2.39	Common to cochlea and utricle
TIME	No	−1.16	Early regeneration
PPARGC1	No	−1.42	Neomycin specific

Proliferation phenotypes were quantified for each siRNA knockdown. Inhibition was determined as a significantly lower proliferation index as compared to a GFP siRNA control (p value < 0.05). Knockdowns of siRNA targets were confirmed by microarray analysis or (*) end-point semi-quantitative PCR.